Insys Therapeutics Advances Oral Cannabinoid Drug for Epilepsy

Insys Therapeutics Inc. (OTC: INSY), a specialty pharmaceutical company developing innovative drug delivery systems and therapeutic molecules, recently announced that it has started dosing pediatric epilepsy patients in a Phase I/II safety and pharmacokinetic study. The patients are pediatric subjects with treatment-resistant seizures, where cannabinoids show promise in helping out. “Rapid advancement of our pharmaceutical CBD program is…

The post Insys Therapeutics Advances Oral Cannabinoid Drug for Epilepsy appeared first on Marijuana Index.